MCID: GST012
MIFTS: 42

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 15
Adenocarcinoma of the Gastroesophageal Junction 73
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4944
NCIt 50 C9296
UMLS 73 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and helicobacter pylori infection, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Dendritic Cells Developmental Lineage Pathway and Adherens junction. The drugs Herceptin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lymph node and lung, and related phenotype is digestive/alimentary.

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.9
2 helicobacter pylori infection 10.1
3 cercarial dermatitis 10.0 IL1B SNAI1
4 exanthem 10.0 ERBB2 TLR9
5 uterine anomalies 10.0 ERBB2 TLR9
6 adenosquamous carcinoma 10.0
7 degos 'en cocarde' erythrokeratoderma 10.0
8 lymphomatous meningitis 10.0
9 female reproductive system disease 9.9 ERBB2 TLR9
10 reproductive system disease 9.9 ERBB2 TLR9
11 parasitic helminthiasis infectious disease 9.9 SNAI1 TLR9
12 respiratory system cancer 9.9 ERBB2 TLR9
13 suppurative otitis media 9.9 IL1B TLR9
14 central nervous system vasculitis 9.9 IL1B TLR9
15 middle ear disease 9.9 IL1B TLR9
16 lacrimal apparatus disease 9.9 IL1B TLR9
17 perinatal necrotizing enterocolitis 9.9 IL1B TLR9
18 extrinsic cardiomyopathy 9.9 IL1B TLR9
19 lymph node disease 9.9 IL1B TLR9
20 keratitis, hereditary 9.9 IL1B TLR9
21 tonsillitis 9.9 IL1B TLR9
22 parasitic protozoa infectious disease 9.9 IL1B TLR9
23 placenta disease 9.9 IL1B TLR9
24 autoimmune disease of central nervous system 9.9 IL1B TLR9
25 bacterial meningitis 9.9 IL1B TLR9
26 meningitis 9.9 IL1B TLR9
27 upper respiratory tract disease 9.9 IL1B TLR9
28 primary bacterial infectious disease 9.9 IL1B TLR9
29 bacterial infectious disease 9.9 IL1B TLR9
30 autoimmune disease of the nervous system 9.9 IL1B TLR9
31 bronchial disease 9.9 IL1B TLR9
32 bone inflammation disease 9.9 IL1B TLR9
33 oral cavity cancer 9.9 ERBB2 TLR9
34 toxoplasmosis 9.9 IL1B TLR9
35 arteries, anomalies of 9.9 IL1B TLR9
36 glucose metabolism disease 9.9 IL1B TLR9
37 trypanosomiasis 9.8 IL1B TLR9
38 immune system disease 9.8 IL1B TLR9
39 intestinal disease 9.8 IL1B TLR9
40 endocrine gland cancer 9.8 ERBB2 TLR9
41 acquired metabolic disease 9.8 IL1B TLR9
42 mouth disease 9.8 IL1B TLR9
43 periodontitis 9.8 IL1B TLR9
44 gastrointestinal system cancer 9.8 ERBB2 SNAI1 TLR9
45 respiratory system disease 9.8 IL1B TLR9
46 keratoconjunctivitis sicca 9.8 ERBB2 IL1B TLR9
47 stomach disease 9.8 ERBB2 IL1B TLR9
48 gastrointestinal system disease 9.8 ERBB2 IL1B TLR9
49 rheumatic disease 9.7 IL1B TLR9
50 chronic granulomatous disease 9.6 IL1B TLR9

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 8.92 ERBB2 GUCY2C SNAI1 TLR9

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Herceptin 18 49 TRASTUZUMAB Genentech October 1998

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 154361-50-9 60953
2
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
3
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
6
Epirubicin Approved Phase 2, Phase 3,Phase 3,Early Phase 1 56420-45-2 41867
7
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
8
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
12
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
13
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
14
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
15
Cetuximab Approved Phase 3,Phase 2 205923-56-4 56842117 2333
16
Tegafur Approved, Investigational Phase 3,Phase 2,Phase 1 17902-23-7 5386
17
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
18
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
19
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
21
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 3,Phase 1 388082-78-8, 231277-92-2 208908 9941095
22 Antimetabolites Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
24 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
25 Angiogenesis Modulating Agents Phase 2, Phase 3
26 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
27 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
28 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
29 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
30 Angiogenesis Inhibitors Phase 2, Phase 3
31
s 1 (combination) Phase 3,Phase 2,Phase 1
32 Immunoglobulins Phase 3,Phase 2,Phase 1
33 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
34 Antibodies Phase 3,Phase 2,Phase 1
35 Mitogens Phase 3,Phase 2,Phase 1
36 Vitamin B9 Phase 3,Phase 2,Phase 1
37 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
40 Folate Phase 3,Phase 2,Phase 1
41 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
42 Appetite Stimulants Phase 3
43 Antiemetics Phase 3
44 Central Nervous System Stimulants Phase 3
45 Analgesics Phase 3,Phase 1
46 Endothelial Growth Factors Phase 3,Phase 1
47 Opiate Alkaloids Phase 3
48 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
49 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Unknown status NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
2 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Unknown status NCT01786278 Phase 2, Phase 3
3 A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Unknown status NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
4 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
5 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
6 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
7 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
8 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
9 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Completed NCT01107639 Phase 3 cisplatin;docetaxel
10 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
11 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed NCT01170663 Phase 3 Placebo;Paclitaxel
12 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
13 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
14 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Recruiting NCT03777657 Phase 3 Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU;Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU
15 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Recruiting NCT03615326 Phase 3 Cisplatin;5-FU;Oxaliplatin;Capecitabine;S-1
16 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
17 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
18 Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Recruiting NCT02381847 Phase 3
19 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05) Recruiting NCT01917552 Phase 3 capecitabine
20 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Recruiting NCT02158988 Phase 3
21 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
22 A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction Gastroesophageal (GEJ) Cancer Recruiting NCT03504397 Phase 3 zolbetuximab;placebo;oxaliplatin;leucovorin;fluorouracil
23 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Active, not recruiting NCT02370498 Phase 3 paclitaxel
24 Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) Active, not recruiting NCT03019588 Phase 3 Paclitaxel
25 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Active, not recruiting NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
26 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
27 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
28 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Active, not recruiting NCT02178956 Phase 3 BBI608;Paclitaxel
29 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting NCT02494583 Phase 3 cisplatin;5-FU;capecitabine
30 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
31 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
32 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
33 A Study of CS1001 in Subjects With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma (GC) or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Not yet recruiting NCT03802591 Phase 3 CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
34 A Randomized Phase III Study Comparing POF (Paclitaxel/Oxaliplatin/Leucovorin/5-FU) With S-1 Plus Docetaxel as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer Not yet recruiting NCT03788226 Phase 3 POF;Docetaxel/S-1
35 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Not yet recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel
36 A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine
37 A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer Terminated NCT01450696 Phase 3 Capecitabine;Cisplatin;Herceptin
38 First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma Terminated NCT01697072 Phase 3 Rilotumumab;Epirubicin;Cisplatin;Capecitabine
39 A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Terminated NCT01641939 Phase 2, Phase 3 Taxane;trastuzumab emtansine;trastuzumab emtansine
40 Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT03083613 Phase 2 Raltitrexed;Paclitaxel
41 Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
42 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
43 Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer Unknown status NCT02525237 Phase 2 Apatinib;S-1
44 Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Unknown status NCT01359397 Phase 2 Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab;Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
45 Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer Unknown status NCT00865982 Phase 2 Docetaxel, Cisplatin, Capecitabine
46 Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Unknown status NCT01855854 Phase 2 Icotinib
47 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
48 Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Completed NCT00515411 Phase 2 Docetaxel, Leucovorin, Fluorouracil, Cisplatin;Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
49 Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00813072 Phase 2 PEP02;irinotecan;docetaxel
50 Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2 irinotecan hydrochloride;cisplatin

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

41
Endothelial, Lymph Node, Lung, Bone, Breast, Pancreas, Placenta

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 123)
# Title Authors Year
1
Perioperative chemotherapy vs. neoadjuvant chemoradiation inA gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. ( 29071366 )
2018
2
Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. ( 29277796 )
2018
3
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. ( 29508095 )
2018
4
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. ( 29094609 )
2018
5
Testicular Metastasis from Recurrent Gastroesophageal Junction Adenocarcinoma: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings. ( 29430123 )
2018
6
Unusual case of left atrial myxoma with gastroesophageal junction adenocarcinoma. ( 29338297 )
2018
7
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ( 29691300 )
2018
8
Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma. ( 29664354 )
2018
9
Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. ( 29666803 )
2018
10
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. ( 29703766 )
2018
11
Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. ( 30483986 )
2018
12
Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. ( 30516569 )
2018
13
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab. ( 30283289 )
2018
14
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. ( 30120163 )
2018
15
Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. ( 28500616 )
2017
16
Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. ( 28524708 )
2017
17
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. ( 28852939 )
2017
18
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. ( 28574779 )
2017
19
Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. ( 29199662 )
2017
20
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. ( 28424936 )
2017
21
External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. ( 28951752 )
2017
22
Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. ( 28491144 )
2017
23
HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )
2017
24
The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis. ( 27424786 )
2017
25
Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? ( 27568322 )
2017
26
Explored Risk Factors for Lymph Node Metastasis with Siewert II/III Adenocarcinoma of the Gastroesophageal Junction. ( 28739759 )
2017
27
Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum. ( 28803334 )
2017
28
Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )
2016
29
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )
2016
30
No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )
2016
31
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )
2016
32
Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )
2016
33
Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )
2016
34
Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction. ( 26250355 )
2016
35
Staging of adenocarcinoma of the gastroesophageal junction. ( 26777127 )
2016
36
Unintentional Long-Term Esophageal Stenting due to a Complete Response in a Patient with Stage UICC IV Adenocarcinoma of the Gastroesophageal Junction. ( 27462189 )
2016
37
Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany. ( 27923357 )
2016
38
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )
2015
39
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )
2015
40
Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )
2015
41
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )
2015
42
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. ( 25530271 )
2015
43
Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )
2014
44
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )
2014
45
Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )
2014
46
Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair. ( 28210138 )
2014
47
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. ( 23739764 )
2014
48
Incidence of microscopically positive proximal margins in adenocarcinoma of the gastroesophageal junction. ( 24505353 )
2014
49
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. ( 24526575 )
2014
50
The role of radiation therapy for resectable adenocarcinoma of the gastroesophageal junction. ( 24729606 )
2014

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.19 IL1B TLR9
2 11.11 ERBB2 SNAI1
3
Show member pathways
10.89 ERBB2 IL1B TLR9
4 10.85 IL1B TLR9
5 10.5 IL1B TLR9

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.61 ERBB2 IL1B TLR9
2 wound healing GO:0042060 9.48 ERBB2 IL1B
3 positive regulation of JNK cascade GO:0046330 9.46 IL1B TLR9
4 positive regulation of interleukin-6 production GO:0032755 9.4 IL1B TLR9
5 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.37 IL1B TLR9
6 positive regulation of epithelial to mesenchymal transition GO:0010718 9.32 IL1B SNAI1
7 positive regulation of JUN kinase activity GO:0043507 9.26 IL1B TLR9
8 positive regulation of interleukin-8 production GO:0032757 9.16 IL1B TLR9
9 regulation of ERK1 and ERK2 cascade GO:0070372 8.96 ERBB2 IL1B
10 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 8.62 IL1B TLR9

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 8.62 IL1B TLR9

Sources for Gastroesophageal Junction Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....